An allele-specific pcr system for rapid detection and discrimination of the CYP2C19*4A, *4B, and *17 alleles: Implications for clopidogrel response testing

Journal of Molecular Diagnostics

Volumn 15, Issue 6, 2013, Pages 783-789

  Scott, Stuart A ^a   Tan, Qian ^a   Baber, Usman ^a   Yang, Yao ^a   Martis, Suparna ^a   Bander, Jeffrey ^a   Kornreich, Ruth ^a   Hulot, Jean Sébastien ^a,b   Desnick, Robert J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ALLELE; ALLELE SPECIFIC POLYMERASE CHAIN REACTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; GENETIC ASSOCIATION STUDIES; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLYMERASE CHAIN REACTION; PRODRUGS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TICLOPIDINE;

EID: 84885993639     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.06.004     Document Type: Article

References (40)

1. A.K. Daly Pharmacogenetics of the cytochromes P450 Curr Top Med Chem 4 2004 1733 1744
2. Z. Desta, X. Zhao, J.G. Shin, and D.A. Flockhart Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958
3. M.J. Price, U.S. Tantry, and P.A. Gurbel The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors Rev Cardiovasc Med 12 2011 1 12
4. S.A. Scott, K. Sangkuhl, A.R. Shuldiner, J.S. Hulot, C.F. Thorn, R.B. Altman, and T.E. Klein PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19 Pharmacogenet Genomics 22 2012 159 165
5. I.C. Gray, C. Nobile, R. Muresu, S. Ford, and N.K. Spurr A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24 Genomics 28 1995 328 332
6. J.A. Goldstein Clinical relevance of genetic polymorphisms in the human CYP2C subfamily Br J Clin Pharmacol 52 2001 349 355
7. S.C. Sim, and M. Ingelman-Sundberg The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects Hum Genomics 4 2010 278 281
8. H.G. Xie, H.C. Prasad, R.B. Kim, and C.M. Stein CYP2C9 allelic variants: ethnic distribution and functional significance Adv Drug Deliv Rev 54 2002 1257 1270
9. K.A. Ross, A.W. Bigham, M. Edwards, A. Gozdzik, G. Suarez-Kurtz, and E.J. Parra Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements J Hum Genet 55 2010 582 589
10. S.A. Scott, R. Khasawneh, I. Peter, R. Kornreich, and R.J. Desnick Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups Pharmacogenomics 11 2010 781 791
11. M. Georgitsi, E. Viennas, V. Gkantouna, E. Christodoulopoulou, Z. Zagoriti, C. Tafrali, F. Ntellos, O. Giannakopoulou, A. Boulakou, P. Vlahopoulou, E. Kyriacou, J. Tsaknakis, A. Tsakalidis, K. Poulas, G. Tzimas, and G.P. Patrinos Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase Pharmacogenomics 12 2011 49 58
12. S. Martis, I. Peter, J.S. Hulot, R. Kornreich, R.J. Desnick, and S.A. Scott Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes Pharmacogenomics J 13 2013 369 377
13. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, K. Bliden, C.P. Cannon, N. Danchin, B. Giusti, P. Gurbel, B.D. Horne, J.S. Hulot, A. Kastrati, G. Montalescot, F.J. Neumann, L. Shen, D. Sibbing, P.G. Steg, D. Trenk, S.D. Wiviott, and M.S. Sabatine Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
14. D.R. Holmes Jr., G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J Am Coll Cardiol 56 2010 321 341
15. J.S. Hulot, J.P. Collet, G. Cayla, J. Silvain, F. Allanic, A. Bellemain-Appaix, S.A. Scott, and G. Montalescot CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients Circ Cardiovasc Interv 4 2011 422 428
16. J.A. Johnson, D.M. Roden, L.J. Lesko, E. Ashley, T.E. Klein, and A.R. Shuldiner Clopidogrel: a case for indication-specific pharmacogenetics Clin Pharmacol Ther 91 2012 774 776
17. J.D. Roberts, G.A. Wells, M.R. Le May, M. Labinaz, C. Glover, M. Froeschl, A. Dick, J.F. Marquis, E. O'Brien, S. Goncalves, I. Druce, A. Stewart, M.H. Gollob, and D.Y. So Point-of-care genetic testing for personalization of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial Lancet 379 2012 1705 1711
18. J.M. Pulley, J.C. Denny, J.F. Peterson, G.R. Bernard, C.L. Vnencak-Jones, A.H. Ramirez, J.T. Delaney, E. Bowton, K. Brothers, K. Johnson, D.C. Crawford, J. Schildcrout, D.R. Masys, H.H. Dilks, R.A. Wilke, E.W. Clayton, E. Shultz, M. Laposata, J. McPherson, J.N. Jirjis, and D.M. Roden Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project Clin Pharmacol Ther 92 2012 87 95
19. O. Gottesman, S.A. Scott, S.B. Ellis, C.L. Overby, A. Ludtke, J.S. Hulot, J. Hall, K. Chatani, K. Myers, J.L. Kannry, and E.P. Bottinger The CLIPMERGE PGx program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics Clin Pharmacol Ther 94 2013 214 217
20. S.A. Scott, K. Sangkuhl, E.E. Gardner, C.M. Stein, J.S. Hulot, J.L. Mega, D.M. Roden, T.E. Klein, M.S. Sabatine, J.A. Johnson, and A.R. Shuldiner Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy Clin Pharmacol Ther 94 2013 317 323
21. J.J. Swen, M. Nijenhuis, A. de Boer, L. Grandia, A.H. Maitland-van der Zee, H. Mulder, G.A. Rongen, R.H. van Schaik, T. Schalekamp, D.J. Touw, J. van der Weide, B. Wilffert, V.H. Deneer, and H.J. Guchelaar Pharmacogenetics: from bench to byte-an update of guidelines Clin Pharmacol Ther 89 2011 662 673
22. S.A. Scott, S. Martis, I. Peter, Y. Kasai, R. Kornreich, and R.J. Desnick Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness Pharmacogenomics J 12 2012 297 305
23. U. Baber, J. Bander, R. Karajgikar, K. Yadav, A. Hadi, K. Theodoropolous, N. Gukathasan, S. Roy, S. Sayeneni, S.A. Scott, J.C. Kovacic, J. Yu, S. Sartori, R. Mehran, J. Uribarri, J. Badimon, P. Muntner, P. Moreno, A.S. Kini, and S.K. Sharma Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity Thromb Haemost 110 2013 118 123
24. S.A. Scott, M. Jaremko, S.A. Lubitz, R. Kornreich, J.L. Halperin, and R.J. Desnick CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing Pharmacogenomics 10 2009 1243 1255
25. S.A. Scott, L. Edelmann, R. Kornreich, M. Erazo, and R.J. Desnick CYP2C9. CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population Pharmacogenomics 8 2007 721 730
26. S.A. Scott, L. Edelmann, R. Kornreich, and R.J. Desnick Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations Am J Hum Genet 82 2008 495 500
27. S.A. Scott, L. Edelmann, L. Liu, M. Luo, R.J. Desnick, and R. Kornreich Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases Hum Mutat 31 2010 1240 1250
28. Y.M. Lo, P. Patel, C.R. Newton, A.F. Markham, K.A. Fleming, and J.S. Wainscoat Direct haplotype determination by double ARMS: specificity, sensitivity and genetic applications Nucleic Acids Res 19 1991 3561 3567
29. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, C.S. Ernest II, D.R. Lachno, D. Salazar, and K.J. Winters Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
30. J.P. Collet, J.S. Hulot, G. Anzaha, A. Pena, T. Chastre, C. Caron, J. Silvain, G. Cayla, A. Bellemain-Appaix, J.B. Vignalou, S. Galier, O. Barthelemy, F. Beygui, V. Gallois, and G. Montalescot High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2) JACC Cardiovasc Interv 4 2011 392 402
31. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, C. Goyenvalle, M. Aiach, P. Lechat, and P. Gaussem Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
32. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, R. Paniccia, S. Valente, D. Antoniucci, R. Abbate, and G.F. Gensini Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
33. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, J.R. Walker, E.M. Antman, W. Macias, E. Braunwald, and M.S. Sabatine Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
34. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, R.B. Horenstein, C.M. Damcott, R. Pakyz, U.S. Tantry, Q. Gibson, T.I. Pollin, W. Post, A. Parsa, B.D. Mitchell, N. Faraday, W. Herzog, and P.A. Gurbel Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
35. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P.G. Steg, J. Ferrieres, N. Danchin, L. Becquemont French Registry of Acute STE, Non STEMII Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
36. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, and G. Montalescot Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
37. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, O. Barthelemy, G. Cayla, F. Beygui, and G. Montalescot Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
38. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, T. Simon, E.M. Antman, E. Braunwald, and M.S. Sabatine Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
39. S.C. Sim, C. Risinger, M.L. Dahl, E. Aklillu, M. Christensen, L. Bertilsson, and M. Ingelman-Sundberg A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 2006 103 113
40. R.J. Ferguson, S.M. De Morais, S. Benhamou, C. Bouchardy, J. Blaisdell, G. Ibeanu, G.R. Wilkinson, T.C. Sarich, J.M. Wright, P. Dayer, and J.A. Goldstein A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin J Pharmacol Exp Ther 284 1998 356 361